Keyes Jason A 4

What Happened Jason A. Keyes, a director of Actuate Therapeutics (ACTU), received a grant/award of 15,000 derivative shares on 2026-05-21. The reported acquisition price is $0.00 (a non-cash award/derivative grant); no cash was exchanged and no shares were sold or exercised in this filing.

Key Details

• Transaction date: 2026-05-21; Form 4 filed 2026-05-22 (timely filing).
• Transaction type/code: Grant / Award (A); derivative security.
• Amount: 15,000 shares; reported price $0.00 (acquired value $0).
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Footnote: F1 — Options will vest in full on the anniversary of the grant date.
• No sale, exercise, or tax-withholding event reported in this transaction.

Context This filing documents a grant of derivative awards (likely stock options or similar) that do not represent immediate market purchases or sales. The award vests in full one year after the grant date per the footnote; until vested and (if applicable) exercised, the awards do not convert into freely tradable shares. The filing was submitted the day after the grant, which is within typical insider reporting timelines.